锌指蛋白397缺陷触发TET2驱动的谱系可塑性与前列腺癌雄激素受体靶向治疗耐药
该研究揭示锌指蛋白397(ZNF397)是雄激素受体(AR)的真正共激活因子,对维持AR驱动的腔样谱系转录程序至关重要。ZNF397缺陷促使癌细胞从AR驱动的腔样谱系向TET2驱动的谱系可塑状态转变,最终促进对AR信号抑制治疗的耐药。TET2抑制剂可消除ZNF397缺陷肿瘤对AR靶向治疗的耐药。
要点
- ZNF397是AR的共激活因子,维持AR驱动的腔样谱系转录程序。
- ZNF397缺陷促进癌细胞向TET2驱动的谱系可塑状态转变,导致AR靶向治疗耐药。
- TET2抑制剂可消除ZNF397缺陷肿瘤对AR靶向治疗的耐药。
核心结论
- ZNF397缺陷通过TET2驱动的表观遗传重编程促进前列腺癌谱系可塑性和AR靶向治疗耐药,TET2抑制剂可逆转此耐药。
研究设计与样本
- 原文未报告研究设计与样本。
主要发现
- ZNF397被鉴定为AR的真正共激活因子,对AR驱动的腔样谱系转录程序必需。
- ZNF397缺陷促进癌细胞从AR驱动的腔样谱系向TET2驱动的谱系可塑状态转变,最终促进对AR信号抑制治疗的耐药。
- TET2抑制剂可消除ZNF397缺陷肿瘤对AR靶向治疗的耐药。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer cells exhibit phenotypical plasticity and epigenetic reprogramming that allows them to evade lineage-dependent targeted treatments by adopting lineage plasticity. The underlying mechanisms by which cancer cells exploit the epigenetic regulatory machinery to acquire lineage plasticity and therapy resistance remain poorly understood. We identified zinc finger protein 397 (ZNF397) as a bona fide coactivator of the androgen receptor (AR), essential for the transcriptional program governing AR-driven luminal lineage. ZNF397 deficiency facilitates the transition of cancer cell from an AR-driven luminal lineage to a ten-eleven translocation 2 (TET2)-driven lineage plastic state, ultimately promoting resistance to therapies inhibiting AR signaling. Intriguingly, our findings indicate that a TET2 inhibitor can eliminate the resistance to AR-targeted therapies in ZNF397-deficient tumors. These insights uncover a novel mechanism through which prostate cancer acquires lineage plasticity via epigenetic rewiring and offer promising implications for clinical interventions designed to overcome therapy resistance dictated by lineage plasticity. Significance: This study reveals a bifurcated role of ZNF397, and a TET2-driven epigenetic mechanism regulating tumor lineage plasticity and therapy response in prostate cancer, enhances the understanding of drug resistance, and unveils a new therapeutic strategy for overcoming androgen receptor-targeted therapy resistance.
引用
- Xu Y, Yang Y, Wang Z, et al. ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer Discov. 2024. PMID: 38591846. doi:10.1158/2159-8290.CD-23-0539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。